Fig. 6: Cytoskeleton- and specifically actin-binding genes are positively associated with ex vivo CDC response to DuoHexaBody-CD37 and with survival in R-CHOP–treated DLBCL patients.

A Dose-response curves of DuoHexaBody-CD37 in CDC assays on B-cells isolated from lymph node suspension cells of DLBCL patients (n = 20). B Maximal CDC response in 16 DLBCL samples stratified into high or low-CDC response, based on correlation between CD37 expression and maximal CDC (%), as well as the expression of total CRP (red color intensity). Asterisks indicate high (n = 4) and low (n = 3) CDC responders selected for transcriptomic analysis. C Principal component analysis (PCA) of RNA-seq data from isolated B-cells of high versus low-CDC responders. D Volcano plot of DEGs (n = 429) between high and low-CDC-sensitive patient samples. E Heat-map showing the top 50 DEGs ranked by log2 fold change between high and low responders. F Top 10 enriched GO terms for biological process (left) and molecular function (right) based on DEGs (log2 fold change < −1 or > 1; n = 411), sorted by false discovery rate (FDR). G Volcano plot showing DEGs (n = 2600) between surviving and deceased DLBCL patients treated with R-CHOP and H top 10 enriched GO terms for biological process (top) and molecular function (bottom) of genes more highly expressed in R-CHOP-treated surviving DLBCL patients (n = 1047), sorted by FDR.